McNEIL PHARMACEUTICAL NEW PRESIDENT IS FORMER MARKETING VP THOMAS ODIORNE, 44
Executive Summary
McNEIL PHARMACEUTICAL NEW PRESIDENT IS FORMER MARKETING VP THOMAS ODIORNE, 44, a 26-year veteran with the company, McNeil announced in a recent press release. Effective since April 15, Odiorne succeeded former McNeil President Jack O'Brien who was promoted to J&J VP-corporate staff for domestic trade relations and development. Included in Odiorne's new responsibilities is McNeil Pharmaceutical Ltd. of Canada. Odiorne has been marketing vice president of McNeil Pharmaceutical. After joining McNeil in 1969, Odiorne held marketing and management positions in the Southwest before moving to the company's Pennsylvania headquarters in 1977 to become product director for Tylenol with codeine, McNeil's Rx acetaminophen combo. In 1979, Odiorne assumed the position of executive director-sales, McNeil said. He followed that promotion with VP-sales in 1982 and became VP-marketing in 1982. Odiorne's early responsibilities as president will include the launch of three new products for which NDAs are currently pending: the peripheral vasodilator, cetiedil; a long-acting form of the anti-psychotic agent Haldol (haloperidol decanoate); and the calcium channel blocker bepridil, which is licensed from Carter Wallace and will be co-marketed with that firm. Another promising McNeil product is 4-hydroxyphenyl retinamide, which was recently recommended for use as a chemopreventive agent against bladder and breast cancer by the Natl. Cancer Institute Div. of Cancer Prevention and Control's Board of Scientific Counselors. The firm's dermatological anti-proliferative agent, fenretinide and two anti-diabetic agents, linogliride fumarate and methyl palmoxirate, are also currently in clinicals.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth